5 Therapies|Clear filters
Reg. name: Vyxeos®
CPX-351 is a liposomal formulation of daunorubicin plus cytarabine co-encapsulated at a molar ratio of 1:5 and it is designed to deliver synergistic drug ratios to leukemia cells.
- Gordon M.J. et al. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leuk Res. Epub 2016 Dec 12;53:39-49. DOI: 10.1016/j.leukres.2016.12.002.
VYXEOS® is indicated for the treatment of adults with newly-diagnosed Therapy-related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC)
Reg. name: Idhifa®
Class: IDH2 inhibitor
Enasidenib is an oral, selective inhibitor of mutated Isocitrate Dehydrogenase 2 (IDH2). Enasidenib binds and inhibits the mutant IDH2 enzyme that is responsible for the accumulation of 2-Hydroxyglutarate (2-HG).
- Mondesir J, et al. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives J Blood Med. 2016; 7: 171–180.
IDHIFA® is indicated for the treatment of adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) with an Isocitrate Dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.